Share Name Share Symbol Market Type Share ISIN Share Description
Ovoca Bio Plc LSE:OVB London Ordinary Share IE00B4XVDC01 EUR0.125
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 10.75 8,916 08:00:03
Bid Price Offer Price High Price Low Price Open Price
10.00 11.50 10.75 10.10 10.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Mining -1.61 -162.48 9
Last Trade Time Trade Type Trade Size Trade Price Currency
13:48:44 O 250 10.0375 GBX

Ovoca Bio (OVB) Latest News

More Ovoca Bio News
Ovoca Bio Investors    Ovoca Bio Takeover Rumours

Ovoca Bio (OVB) Discussions and Chat

Ovoca Bio Forums and Chat

Date Time Title Posts
05/1/202110:18Ovoca cap Ј8.8, stake in Polymetal worth Ј14.8176
21/12/202016:32Viagra for women663

Add a New Thread

Ovoca Bio (OVB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-22 13:48:4610.0425025.09O
2021-01-22 11:11:3510.9944148.47O
2021-01-22 09:17:3310.005,731573.10O
2021-01-22 09:03:0210.002,494249.40O
View all Ovoca Bio trades in real-time

Ovoca Bio (OVB) Top Chat Posts

Ovoca Bio Daily Update: Ovoca Bio Plc is listed in the Mining sector of the London Stock Exchange with ticker OVB. The last closing price for Ovoca Bio was 10.75p.
Ovoca Bio Plc has a 4 week average price of 8.53p and a 12 week average price of 8.50p.
The 1 year high share price is 19.25p while the 1 year low share price is currently 6.75p.
There are currently 81,563,806 shares in issue and the average daily traded volume is 15,028 shares. The market capitalisation of Ovoca Bio Plc is £8,768,109.15.
dave4545: You look around and stocks issuing none or moderate news and they are going up with incredible valuations. Ovb market cap is close to their cash + Poly stake so the drug is still being valued for nothing. They spent £4 mil buying buying 40% they did not own of IVIX So that is valued at £10 million, add that together, throw in some token value for the potential seeing as previous trials had all been positive and you get a £25-30 mil valuation 3 times the current price or around 33-35p It spiked to that price in 2019
dave4545: The good thing for Ovb is if they need cash they can easily sell Poly shares without damaging the price. I'd still guess cash + Poly stake is going to be around £8-12 mil so drug is valued at zero which has been the case for over a year now
fillipe: Today's news well received. f
fillipe: A strong demand for OVB this morning, taking advantage of this relatively minor and temporary setback. f
euclid5: Polymetal announces that on 25 August 2020 the Board of Directors of the Company resolved to pay an interim dividend of US$ 0.40 per share for the six months ended 30 June 2020 This brings the total dividend declared in 2020 to US$ 1.02 per share, or US$ 481 million in aggregate, and the dividend yield to 5.4% based on the average year-to-date share price. The dividend will be paid on 25 September 2020 Https://
dave4545: 6.4% wow just checked myself. In a normal share world they could have sold them today and then RNS tomorrow to say they have and they have £10 mil cash. Imagine what that would do for the share price, instead since day 1 they sell in silence and then disclose in annual reports. Pr is always poor.
imastu pidgitaswell: I don't disagree - just thinking that while it is cash burning, the increase in value of the POLY stake is really extending the period that it can undertake the development, rather than being a reason for the company value to rise (which is dependent on the efficacy of the drug.) Or put another way, the value of the liquid investment/cash does not affect the chances of the drug success - which is (possibly) why the share price remains unaffected. If they were to close the company today and return everything to shareholders, then it would be a factor - but that is not going to happen.
imastu pidgitaswell: I would imagine it's simply being valued as a drugs play. The shareholding in POLY is simply the funding source - it will get spent, and the increase in value is just extending the time for which the funding source will be available. It's a very imaginative source (albeit more an accident/legacy) which is a whole lot better than cash, but still only a means to an end - this is not an investment vehicle for POLY (I hold their shares). Which is nice, but not really a reason for the share price here to increase - that is fundamentally an issue of the likelihood the drug working - or not (I have no opinion on that.)
dave4545: Right I'll update the current numbers. Ovb held 1.405 million Polymetal shares. In 3 reported transactions they sold 630k, 170k and 145k That's 945k leaving 460k of Poly shares left who are trading at £15.50 Lets assume they sold at the 630k at average of £10 a share as price traded between £8 and £12 in that period and let assume because of the big strength in Pol price they sold the other 305k for £12 minimum that is £10 mil raised. They already had some cash on the books but assume some is lost for admin costs during the year. They spent £4 mil of that buying our the remaining stake they did not own. So they should have now a minimum of £6 mil cash + stake in Poly worth £7 million A drug with a very promising phase 111 trail in Russia last year and now moving to a safer country Australia to do future trials. Market cap £'s a very unloved stock that should be trading at double the price to reach some kind of fair value
sep800: MARKET CAP £35M PLUS IMMINENT What we are witnessing as to my previous posts highlighting the massive anticipated uplift in the current share price is the conditiued increasing number of Patents being granted Globally. With this in Mind and with further Patents being granted, The processing of teaming a fully production/Manufacturing vehicle is currently in negotiations. OVB have stated that their aim is to be a Manufacturer too. OVB are targeting Globally with its Libicore formula and are exposed to the might of Pharmaceutical companies that would want the control of the entire Patent. Is OVB being targeted behind the scenes for a complete buyout or JV. They have spent £MM's in R & D and years progressing to achieve where they are today and accepting a generous offer from a major will become more realistic as each day passes. There will be 2 options 1. An overall buyout ( Offers in access £50M plus ) 2. A JV with Licences granted to third parties Globally and receiving Royalties This will and should re-rate the M/C to £35M Plus. The above figures are conservative pending the cost of each course. There will be many doubters here but one really needs to look further into what really is happening behind the scenes. This company is growing rapidly and faster than we all think. Any announcement confirming that OVB have been approached by a major or discussing a JV interested in their product will catapult the share price to 30p-50p. This is a multi-£BN Market and even £1plus per share is reasonable once production is announced.
Ovoca Bio share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Ovoca Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 02:52:04